Most Read

Forxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that is administered orally once every day. It has shown efficacy in preventing and delaying cardiorenal disease, while protecting the

Located at the Research Triangle Park (RTP), the facility has nearly 3,300m2 of total gross floor area and will provide additional manufacturing capacity to produce autologous CAR T-cell

Spesolimab is a new selective antibody that inhibits the interleukin-36 receptor (IL-36R) signalling activation. It is claimed to be the first treatment option approved to treat GPP flares.

IPX203 is a new oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules that comprises extended-release (ER) coated beads and immediate-release (IR) granules. The company’s NDA submission is based on

The lipid-peptide analog, OK-101 comprises a 12 amino acid peptide sequence, an anchoring lipid domain, and a linker component. It has been developed using a new membrane-anchored peptide

Scemblix specifically targets the ABL myristoyl pocket, which is also called as a STAMP inhibitor in scientific literature. It provides a new treatment approach for patients experiencing intolerance

The vaccine has been authorised for use in adolescents aged 12 to 17 years. The protein-based vaccine, Nuvaxovid is engineered from the genetic sequence of the initial SARS-CoV-2

Ultomiris is a long-acting C5 complement inhibitor that provides immediate, complete and sustained complement inhibition. It is indicated for adult gMG patients, who are anti-acetylcholine receptor (AChR) antibody-positive,

Under the terms of the deal, the company will facilitate access to its monkeypox vaccines in Latin America and the Caribbean, as well as the countries that participate